Comparison · NCT02024555-sae
Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin vs Placebo: serious adverse events. Trial comparisons, record NCT02024555-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02024555-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0816 | 0.0322 | 0.192 | wilson | |
| Risk in group 2 | 0.0625 | 0.0215 | 0.168 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0191 | -0.0977 | 0.137 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.31 | 0.309 | 5.53 | log | |
| Odds ratio, group 1 over group 2 | 1.33 | 0.282 | 6.3 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin than on Placebo | 52.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin | Levofloxacin 500mg po QD; Ethambutol 1200mg po QD; Azithromycin 250 mg po QD; Rifampin 600mg po QD or Rifabutin 300mg po QD~Levofloxacin~Ethambutol~Azithromycin~Rifampin | 4 | 49 | EG000 |
| Group 2 | Placebo | Riboflavin will be used for rifampin; encapsulated microcrystalline cellulose will be used to replace the levofloxacin, ethambutol and azithromycin.~The pill count will be the same as the comparator regimen.~Placebo: This will serve as a placebo to the antibiotics used in antimycobacterial therapy. | 3 | 48 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 24 weeks
Source ClinicalTrials.gov
Trial
- Title
- Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
- NCT number
- NCT02024555
- Phases
- PHASE2
- Conditions
- Sarcoidosis; Antimycobacterial Therapy
- Interventions
- Levofloxacin, Ethambutol, Azithromycin, Rifampin, Placebo
- Lead sponsor
- Vanderbilt University
- Results first posted
- 2020-07-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02024555?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02024555-sae